Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Capital Expenditures for 10 consecutive years, with $938000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 475.46% to $938000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 14.29% decrease, with the full-year FY2025 number at $6.0 million, down 14.29% from a year prior.
  • Capital Expenditures was $938000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $1.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $66.1 million in Q3 2022 to a low of -$71.2 million in Q4 2022.
  • A 5-year average of $3.0 million and a median of $1.9 million in 2025 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 183.04% in 2021, then skyrocketed 1792.29% in 2023.
  • Ultragenyx Pharmaceutical's Capital Expenditures stood at -$38.1 million in 2021, then crashed by 87.09% to -$71.2 million in 2022, then surged by 54.11% to -$32.7 million in 2023, then soared by 100.5% to $163000.0 in 2024, then soared by 475.46% to $938000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Capital Expenditures are $938000.0 (Q4 2025), $1.3 million (Q3 2025), and $2.2 million (Q2 2025).